logo
North Fourth Street in front of Grand Forks Central High School to close beginning May 27

North Fourth Street in front of Grand Forks Central High School to close beginning May 27

Yahoo22-05-2025

May 21—GRAND FORKS — North Fourth Street in front of Grand Forks Central High School will be closed beginning May 27.
The closure will be in place until mid-October between First Avenue North and Second Avenue North, according to a city release. The city is working to improve the stretch of road in a $2.8 million project. Around $2 million of the project is being federally funded through the urban grants programs and approximately $774,000 million being funded locally.
During the project, pedestrian access will be retained in front of City Hall and the high school, but there will be no access to the parking lot between the two buildings. Additionally, the intersection of North Fourth Street and Second Avenue North will be closed.
On-street parking will remain in unaffected areas and public parking will remain available after 5 p.m. at the Central Ramp, City Hall parking lot and parking lot on the north corner of University Avenue and North Fourth Street.
In addition to street improvements, there will also be improvements to ADA access and streetscapes, matching those along DeMers Avenue and other parts of downtown. A previously proposed mid-block crossing in front of Central High School
is not included in the design as the space between intersections would be too small.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

St. Paul weighs consolidating some downtown offices at Osborn 370 building
St. Paul weighs consolidating some downtown offices at Osborn 370 building

Yahoo

time15 hours ago

  • Yahoo

St. Paul weighs consolidating some downtown offices at Osborn 370 building

The city of St. Paul plans to lease more than 10,000 square feet within the Osborn 370 building on Wabasha Street, covering the building's entire ninth floor, for eight years. What will that square footage be used for? Therein lies the question. The lease at 9 Fifth St. E., approved Wednesday by the St. Paul City Council, allows for flexible move-in dates and below-market rates, with the first 12 months rent-free. That gives the city some time to complete a 'space use' study with the help of real estate consultants, who will attempt to determine which city offices will make best use of the new floor and in what manner. It might become collaborative work space for the city to engage with private sector partners, or it may support departments with space shortages, such as the city attorney's office. It also may be used as upgraded space for staff committed to working downtown more than three days per week, said Bruce Engelbrekt, the city's real estate manager, addressing the city council on Wednesday. With many office staff on a hybrid work schedule, St. Paul Mayor Melvin Carter floated the idea last year of clearing out the downtown City Hall Annex building on Fourth Street and converting the property into residences, which remains a possibility. 'We're trying to think strategically about how to use our purchasing power and people power to help be part of the solution,' said Council President Rebecca Noecker. City offices are largely but not exclusively spread throughout the City Hall/Ramsey County Courthouse building at 15 West Kellogg Blvd. and the annex building directly across the street. The city's Department of Safety and Inspections works out of a building on Jackson Street, which is owned by Madison Equities, an embattled downtown property owner that has recently lost control of some of its buildings to foreclosure and receivership. The study likely will at least touch on library staff based at the downtown George Latimer Central Library. 'We have a question into (the consultants) whether the mayor's office and the city council offices should be part of the study, because of your need to be located in this building,' Engelbrekt said. 'We need to specifically look at those (offices) that have some space needs.' Council Member Cheniqua Johnson noted Osborn 370 has developed a positive reputation downtown, drawing notable tenants such as the St. Paul and Minnesota Foundation. The Osborn 370 floor is partially furnished, allowing 'minimal up-front investment to move and establish operations,' according to the council resolution approved Wednesday. St. Paul's Maxfield Elementary breaks ground on 'community schoolyard' Ex-teacher of Hmong College Prep Academy in St. Paul sentenced for criminal sexual conduct with student Four candidates file for Ward 4 seat on the St. Paul City Council Canadian wildfire smoke causes 'very unhealthy' conditions in American Midwest and reaches Europe 40 St. Paul street lights stripped of copper wiring, though reports are down overall

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Yahoo

time20 hours ago

  • Yahoo

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientific Sessions of the American Diabetes Association® (ADA). 'We look forward to presenting work spanning our portfolio to the scientific community at this year's ADA meeting,' said Whit Bernard, Chief Executive Officer of Metsera. 'Our presentations, including clinical data from the completed Phase 1/2 trial of MET-097i and preclinical findings for our other programs, showcase the breadth of our next-generation approaches to address the need for scalable and differentiated treatments for overweight and obesity.' Presentation Highlights MET-097i: A fully biased, ultra-long acting GLP-1 receptor agonist MET-097i is Metsera's fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i's Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a single candidate monthly dose. MET-233i: An ultra-long acting amylin analog MET-233i is Metsera's monthly, ultra-long acting amylin analog. Metsera will present preclinical data, including detailed pharmacokinetic and change in body weight data. Presentation Details: MET-097i: A fully biased ultra-long acting GLP-1 receptor agonist Clinical data Title: A Twelve-Week Trial of MET-097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (788-P)Session: Sunday General Poster SessionPresenter: Robert Stoekenbroek, M.D., Ph.D., Head of Portfolio Strategy at Metsera Time/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 122 Title: Safety, Tolerability, PK, and Efficacy of MET-097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management (753-P)Session: Sunday General Poster SessionPresenter: Steve Marso, M.D., Chief Medical Officer at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 088 Preclinical data Title: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (794-P)Session: Sunday General Poster SessionPresenter: Charlotte Hinds, Ph.D., Senior Director, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 128 Title: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist (799-P)Session: Sunday General Poster SessionPresenter: Billy Peter Baxter, Ph.D., Imperial College LondonTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 133 MET-233: An ultra-long acting amylin analog Preclinical data Title: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist (894-P)Session: Sunday General Poster SessionPresenter: James S Minnion, Ph.D., Vice President, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 190 Pipeline programs Preclinical data Title: Therapeutic NuSH Cocktails—Coadministration of Ultra-Long-Acting GLP-1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice (765-P)Session: Sunday General Poster SessionPresenter: Robert Hansford, Ph.D., Preclinical Research Scientist at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 100 Health Economics and Outcomes Research Title: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset (758-P)Session: Sunday General Poster SessionPresenter: Shannon Armstrong, Vice President, Global Value and Access at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 093 For more information about Metsera's presence at ADA, visit About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation and presentations at the 85th Scientific Sessions of the American Diabetes Association® (ADA), its research and development activities, and statements regarding the efficacy, safety and potential regulatory progress of its investigational candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera's business outlined in Metsera's filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera's actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact:Jono EmmettMetseramedia@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Yahoo

timea day ago

  • Yahoo

Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientific Sessions of the American Diabetes Association® (ADA). 'We look forward to presenting work spanning our portfolio to the scientific community at this year's ADA meeting,' said Whit Bernard, Chief Executive Officer of Metsera. 'Our presentations, including clinical data from the completed Phase 1/2 trial of MET-097i and preclinical findings for our other programs, showcase the breadth of our next-generation approaches to address the need for scalable and differentiated treatments for overweight and obesity.' Presentation Highlights MET-097i: A fully biased, ultra-long acting GLP-1 receptor agonist MET-097i is Metsera's fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i's Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a single candidate monthly dose. MET-233i: An ultra-long acting amylin analog MET-233i is Metsera's monthly, ultra-long acting amylin analog. Metsera will present preclinical data, including detailed pharmacokinetic and change in body weight data. Presentation Details: MET-097i: A fully biased ultra-long acting GLP-1 receptor agonist Clinical data Title: A Twelve-Week Trial of MET-097—A Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (788-P)Session: Sunday General Poster SessionPresenter: Robert Stoekenbroek, M.D., Ph.D., Head of Portfolio Strategy at Metsera Time/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 122 Title: Safety, Tolerability, PK, and Efficacy of MET-097—A Next-Generation Nutrient-Stimulated Hormone Peptide Analog for Chronic Weight Management (753-P)Session: Sunday General Poster SessionPresenter: Steve Marso, M.D., Chief Medical Officer at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 088 Preclinical data Title: MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist (794-P)Session: Sunday General Poster SessionPresenter: Charlotte Hinds, Ph.D., Senior Director, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 128 Title: Cellular Characterisation of Signalling and Receptor Trafficking Induced by MET-097, a G Protein-Biased GLP-1R Agonist (799-P)Session: Sunday General Poster SessionPresenter: Billy Peter Baxter, Ph.D., Imperial College LondonTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 133 MET-233: An ultra-long acting amylin analog Preclinical data Title: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist (894-P)Session: Sunday General Poster SessionPresenter: James S Minnion, Ph.D., Vice President, Research & Development at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 190 Pipeline programs Preclinical data Title: Therapeutic NuSH Cocktails—Coadministration of Ultra-Long-Acting GLP-1, GIP, Glucagon, and Amylin Peptide Analogs Induce Profound Weight Loss in DIO Mice (765-P)Session: Sunday General Poster SessionPresenter: Robert Hansford, Ph.D., Preclinical Research Scientist at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 100 Health Economics and Outcomes Research Title: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset (758-P)Session: Sunday General Poster SessionPresenter: Shannon Armstrong, Vice President, Global Value and Access at MetseraTime/Date: Sunday, June 22; 12:30-1:30pm CDTLocation: Poster Hall (Hall F1), 093 For more information about Metsera's presence at ADA, visit About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at and follow us on LinkedIn and X. Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at In addition, you may sign up to automatically receive email alerts and other information about the Company by using the 'Email Alerts' option on the Investors & Media page and submitting your email address. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Examples of such statements include, but are not limited to, statements relating to Metsera's expectations regarding participation and presentations at the 85th Scientific Sessions of the American Diabetes Association® (ADA), its research and development activities, and statements regarding the efficacy, safety and potential regulatory progress of its investigational candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Metsera's business outlined in Metsera's filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of its Annual Report on Form 10-K for the year ended December 31, 2024. Forward-looking statements are not guarantees of future performance, and Metsera's actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Metsera makes in this press release speak only as of the date of this press release. Metsera assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact:Jono EmmettMetseramedia@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store